HC Wainwright Has Lowered Expectations for X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price

X4 Pharmaceuticals (NASDAQ:XFOR) had its price target trimmed by HC Wainwright from $5.00 to $1.50 in a report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Stifel Nicolaus cut their target price on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $0.40 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 6.04. The firm has a 50-day moving average of $0.58 and a two-hundred day moving average of $0.74. The stock has a market cap of $68.82 million, a P/E ratio of -4.48 and a beta of 0.39. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 239,436 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the transaction, the chief executive officer now directly owns 1,057,713 shares in the company, valued at $581,742.15. This trade represents a 18.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Adam S. Mostafa sold 230,645 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $126,854.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 580,800 shares of company stock worth $321,447. 1.62% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after buying an additional 12,514 shares in the last quarter. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals during the third quarter worth approximately $30,000. SG Americas Securities LLC bought a new stake in X4 Pharmaceuticals during the third quarter worth approximately $37,000. XTX Topco Ltd bought a new stake in X4 Pharmaceuticals during the second quarter worth approximately $65,000. Finally, Rhumbline Advisers boosted its holdings in X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after buying an additional 23,831 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.